case_images: PMC11347432_01
case_images: (A) Brain and scalp radiotherapy plans (51Gy/17f). (B) Mediastinum and vertebral body radiotherapy plans (mediastinum: 56Gy/8f, vertebral body: 40Gy/5f). (C) Whole brain radiotherapy (24Gy/8f) and additional dose of all intracranial and scalp lesions (24Gy/8f).
case_images: fphar-15-1431542-g002.jpg
case_images: PMC11347432_01_fphar-15-1431542-g002.jpg
case_images: F2
case_images: CK20 (+), CDX2 (+), CK7 (-), CK5/6 (-), TIF-1 (-), Ki-67: 80% and HER2 diffuse positive. Capecitabine following the head radiotherapy (51Gy/17f) was performed (Figure 2A). In August 2023, the patient received trastuzumab + pertuzumab, followed by mediastinal and pyramidal radiotherapy with a dosage of 56Gy/8f, and 40Gy/5f respectively (Figure 2B). Then tegafur, pyrotinib combined with head radiotherapy (48Gy/16f) was recommended by the oncologists in October 2023 (Figure 2C).
case_images: Clinical images of the patient.
case_images: fphar-15-1431542-g003.jpg
case_images: PMC11347432_01_fphar-15-1431542-g003.jpg
case_images: F3
case_images: Besides, the multiple metastases in the lung, pancreatic head, both kidneys and paraaortic lymph nodes were also dramatically shrunk (Figure 3).